Mubang (Beijing) Pharmaceutical Technology Co., Ltd.

Main study objectives: To observe the relative bioavailability of a single oral tablet (fasting and postprandial) of the test preparation indobufen tablets (specification: 0.2 g/tablet, provided by Mubang (Beijing) Pharmaceutical Technology Co., Ltd.) and the reference preparation indobufen tablets (Ibustrin®, specification: 200 mg/tablet, produced by Pfizer Italia S.r.l.) in healthy Chinese subjects, analyze the pharmacokinetic parameters of the two preparations, and evaluate the bioequivalence of the two preparations. Secondary study objectives: To evaluate the safety of a single oral tablet of the test preparation and the reference preparation indobufen tablets under fasting and postprandial conditions in healthy Chinese subjects.

The main purpose of the study is to evaluate the pharmacokinetics of the test preparation empagliflozin tablets 25 mg and the reference preparation empagliflozin tablets (JARDIANCE®) 25 mg in healthy adult subjects, and to evaluate the oral bioequivalence of the two preparations in the fasting/fed state. The secondary purpose of the study is to observe the safety of the test preparation empagliflozin tablets and the reference preparation empagliflozin tablets (JARDIANCE®) in healthy people.

The main purpose of the study is to study the pharmacokinetics of the test preparation canagliflozin tablets 100 mg and the reference preparation "INVOKANA®" 100 mg in healthy adult subjects after fasting and after meals, and to evaluate the bioequivalence of the test preparation and the reference preparation of canagliflozin tablets after fasting and after meals. Secondary purpose of the study is to study the safety of the test preparation canagliflozin tablets 100 mg and the reference preparation "INVOKANA®" 100 mg in healthy adult subjects.